Key Takeaways:
Elicio Therapeutics' KRAS-targeting immunotherapy missed its primary endpoint in a Phase 2 pancreatic cancer trial, but post-hoc data may have salvaged a path to registration.
Elicio Therapeutics Inc. shares collapsed 72% to $4.08 on Monday after its lead candidate, ELI-002 7P, failed to meet the primary endpoint of disease-free survival in a Phase 2 trial for adjuvant KRAS-mutant pancreatic cancer — a result the company attributed to an imbalance in patients with higher residual disease burden.
"The results are more nuanced than they initially appear," H.C. Wainwright analyst Robert Burns wrote in a note, calling the sell-off "an attractive entry point." The 144-patient AMPLIFY-7P study randomized patients across 24 US sites to receive ELI-002 7P or observation following surgery and standard locoregional therapy. While the intent-to-treat analysis missed its prespecified DFS endpoint, post-hoc landmark assessments showed approximately 14% absolute improvement in DFS rates at three months (90.3% versus 76.6%, p=0.022) and six months (75.7% versus 61.7%, p=0.056), with treatment-arm separation persisting through nine months.
The primary confound was an imbalance in R1 resection status — where microscopic residual disease remains at the surgical margin — which affected 19% of patients in the treatment arm versus 10% in the observation arm. R1 status is a known negative prognostic factor associated with earlier recurrence and poorer survival. When the analysis was restricted to R0-resected patients, who had no detectable residual disease and represented approximately 84% of the enrolled population, the treatment effect strengthened to a hazard ratio of 0.65. Median DFS for R0 patients reached 23.8 months in the treatment arm versus 12.8 months in the observation cohort, and at 18 months, absolute recurrence rates were 9.5% lower in the treatment group.
The Biology Behind the Signal
ELI-002 7P is built on Elicio's AMP platform, originally developed at the Massachusetts Institute of Technology, which delivers immunotherapy directly to lymph nodes by binding to albumin as it travels through lymphatic tissue. The seven-peptide formulation targets the seven most common KRAS mutations, which drive approximately 25% of all solid tumors. The drug is administered subcutaneously and combines AMP-modified mutant KRAS peptide antigens with an AMP-modified CpG oligodeoxynucleotide adjuvant.
The trial validated the platform's mechanism at the biological level. Patients with the strongest mKRAS-specific T-cell responses — defined as greater than 9.17-fold change from baseline — experienced significantly improved DFS compared with lower responders (HR 0.22, p<0.0001, n=90 evaluable). "These findings show the promise of immunological targeting of mKRAS in patients previously considered to be refractory to immunotherapy," said Eileen M. O'Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center.
A Crowded Field and a Tight Cash Runway
The mixed data arrive during a breakthrough period for pancreatic cancer treatment. In April, Revolution Medicines' RAS inhibitor daraxonrasib doubled survival in a Phase 3 trial, and at the American Society of Clinical Oncology meeting last month, Immuneering reported that its MEK-targeting inhibitor atebimetinib elicited 17.3 months median overall survival versus 8.5 months for standard of care. Pancreatic cancer carries just a 13% five-year survival rate, making it one of the deadliest malignancies.
Elicio plans to advance ELI-002 7P into a Phase 3 registrational study focused exclusively on R0-resected patients, with extended dosing beyond the initial immunization and booster regimen used in Phase 2. The company reported a favorable safety profile with no treatment-related discontinuations or deaths. However, the path forward depends on financing: Elicio's cash supports operations only into the fourth quarter of 2026, and the company said it is evaluating strategic financing and partnership opportunities. The company reported zero revenue and a widening net loss in its first-quarter 2026 results.
Elicio shares, which had traded above $14 before the announcement, now carry a market capitalization of roughly $60 million. The company faces potential shareholder litigation — SueWallSt announced an investigation into Elicio's officers and directors on Tuesday — and must secure additional capital to fund its Phase 3 program. For investors, the question is whether the biological signal in R0 patients and the validated immune mechanism can attract a partner before the cash runs out.
This article is for informational purposes only and does not constitute investment advice.
